PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Drug ReportsDofetilide
Tikosyn(dofetilide)
Dofetilde, Dofetilide, Tikosyn (dofetilide) is a small molecule pharmaceutical. Dofetilide was first approved as Tikosyn on 1999-10-01. It is used to treat atrial fibrillation, atrial flutter, and cardiac arrhythmias in the USA. It has been approved in Europe to treat atrial fibrillation and atrial flutter. The pharmaceutical is active against voltage-gated inwardly rectifying potassium channel KCNH2; potassium voltage-gated channel subfamily H member 2. In addition, it is known to target voltage-gated delayed rectifier potassium channel KCNH1; potassium voltage-gated channel subfamily H member 1.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
cardiovascular diseasesD002318
signs and symptoms pathological conditionsD013568
Trade Name
FDA
EMA
Dofetilde, Dofetilide, Tikosyn (discontinued: Dofetilide)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Dofetilide
Tradename
Company
Number
Date
Products
TIKOSYNPfizerN-020931 RX1999-10-01
3 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
dofetilideANDA2024-11-13
dofetilide 0.125mg dofetilide 0.25mg dofetilide 0.5mgANDA2024-11-14
tikosynNew Drug Application2024-10-21
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
atrial fibrillationEFO_0000275D001281I48.0
atrial flutterEFO_0003911D001282—
cardiac arrhythmiasEFO_0004269D001145I49.9
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
C: Cardiovascular system drugs
— C01: Cardiac therapy drugs
— C01B: Antiarrhythmics, class i and iii
— C01BD: Antiarrhythmics, class iii
— C01BD04: Dofetilide
HCPCS
No data
Clinical
Clinical Trials
21 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Atrial fibrillationD001281EFO_0000275I48.0——33713
Cardiac arrhythmiasD001145EFO_0004269I49.9———134
CardiomyopathiesD009202EFO_0000318I42———1—1
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Heart failureD006333HP_0001635I50——1——1
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Long qt syndromeD008133HP_0001657I45.8141——15
SyndromeD013577——11———1
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
PharmacokineticsD010599——2————2
Pharmacological phenomenaD000069437——2————2
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Drug-related side effects and adverse reactionsD064420—T88.7————11
Atrial flutterD001282EFO_0003911—————11
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameDofetilide
INNdofetilide
Description
Dofetilide is a tertiary amino compound that is N-ethyl-N-methylethanamine substituted by a 4-[(methylsulfonyl)amino]phenoxy and a 4-[(methylsulfonyl)amino]phenyl group at the terminal carbon atoms respectively. It is used as an anti-arrhythmia drug. It has a role as an anti-arrhythmia drug and a potassium channel blocker. It is a sulfonamide, an aromatic ether and a tertiary amino compound.
Classification
Small molecule
Drug classclass III antiarrhythmic agents
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
CN(CCOc1ccc(NS(C)(=O)=O)cc1)CCc1ccc(NS(C)(=O)=O)cc1
Identifiers
PDB—
CAS-ID115256-11-6
RxCUI—
ChEMBL IDCHEMBL473
ChEBI ID4681
PubChem CID71329
DrugBankDB00204
UNII IDR4Z9X1N2ND (ChemIDplus, GSRS)
Target
Agency Approved
KCNH2
KCNH2
Organism
Homo sapiens
Gene name
KCNH2
Gene synonyms
ERG, ERG1, HERG
NCBI Gene ID
3757
Protein name
potassium voltage-gated channel subfamily H member 2
Protein synonyms
Eag homolog, Eag-related protein 1, ERG-1, Ether-a-go-go-related gene potassium channel 1, ether-a-go-go-related potassium channel protein, Ether-a-go-go-related protein 1, H-ERG, hERG-1, hERG1, human ether-a-go-go-related, long QT syndrome type 2, potassium channel, voltage gated eag related subfamily H, member 2, potassium voltage-gated channel, subfamily H (eag-related), member 2, Voltage-gated potassium channel subunit Kv11.1
Uniprot ID
Q9H3P0
Mouse ortholog
Kcnh2 (16511)
potassium voltage-gated channel subfamily H member 2 (O35989)
Alternate
KCNH1
KCNH1
Organism
Homo sapiens
Gene name
KCNH1
Gene synonyms
EAG, EAG1
NCBI Gene ID
3756
Protein name
potassium voltage-gated channel subfamily H member 1
Protein synonyms
EAG channel 1, ether-a-go-go 1, Ether-a-go-go potassium channel 1, ether-a-go-go, Drosophila, homolog of, h-eag, hEAG1, potassium channel, voltage gated eag related subfamily H, member 1, potassium voltage-gated channel, subfamily H (eag-related), member 1, Voltage-gated potassium channel subunit Kv10.1
Uniprot ID
Q14CL3
Mouse ortholog
Kcnh1 (16510)
potassium voltage-gated channel subfamily H member 1 (Q60603)
Variants
No data
Financial
Revenue by drug
$
€
£
₣
Tikosyn – Pfizer
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 2,954 documents
View more details
Safety
Black-box Warning
Black-box warning for: Dofetilide, Dofetilide 0.125mg dofetilide 0.25mg dofetilide 0.5mg, Tikosyn
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
8,428 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use